RxDoctor Payments Data

Lindsay Gonzalez

Family · Austin, TXNPI 1982300505

Payments from drug & device makers

$4,092in general payments, 2019–2025

Across 40 payments — averaging $102.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$404
  • Sanofi$370
  • AbbVie$329
  • AstraZeneca$303
  • Neurocrine Biosciences, Inc.$293
  • Biotronik NRO, Inc.$279
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,092 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$133,018
Medicare patients
126
Services billed
1,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$12,593
EliquisApixaban26$8,150
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$1,655
Acitretin11$1,650
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,552
Divalproex Sodium25$1,458
Atorvastatin Calcium112$1,354
Entacapone18$1,342
Trazodone Hcl63$1,022
Gabapentin75$974
Tramadol Hcl14$727
Pantoprazole Sodium12$654
Lisinopril46$577
Fenofibrate13$565
Albuterol Sulfate HfaAlbuterol Sulfate18$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$104$12,59311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →